[go: up one dir, main page]

PT1686997E - Inibidores da forma mutante de kit - Google Patents

Inibidores da forma mutante de kit Download PDF

Info

Publication number
PT1686997E
PT1686997E PT04818795T PT04818795T PT1686997E PT 1686997 E PT1686997 E PT 1686997E PT 04818795 T PT04818795 T PT 04818795T PT 04818795 T PT04818795 T PT 04818795T PT 1686997 E PT1686997 E PT 1686997E
Authority
PT
Portugal
Prior art keywords
kit
inhibitors
mutant form
mutant
administered
Prior art date
Application number
PT04818795T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1686997E publication Critical patent/PT1686997E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT04818795T 2003-11-18 2004-11-17 Inibidores da forma mutante de kit PT1686997E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18

Publications (1)

Publication Number Publication Date
PT1686997E true PT1686997E (pt) 2009-07-17

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04818795T PT1686997E (pt) 2003-11-18 2004-11-17 Inibidores da forma mutante de kit

Country Status (27)

Country Link
US (3) US8017621B2 (pt)
EP (2) EP1686997B1 (pt)
JP (3) JP4762150B2 (pt)
KR (1) KR101153647B1 (pt)
CN (3) CN102274230B (pt)
AT (1) ATE428426T1 (pt)
AU (1) AU2004290902B2 (pt)
BR (1) BRPI0416680A (pt)
CA (1) CA2546189C (pt)
CY (1) CY1110354T1 (pt)
DE (1) DE602004020654D1 (pt)
DK (1) DK1686997T3 (pt)
ES (1) ES2324917T3 (pt)
HR (1) HRP20090390T1 (pt)
IL (2) IL175578A (pt)
MA (1) MA28176A1 (pt)
MX (1) MXPA06005598A (pt)
NO (1) NO20062694L (pt)
NZ (1) NZ547195A (pt)
PL (1) PL1686997T3 (pt)
PT (1) PT1686997E (pt)
RU (2) RU2362562C2 (pt)
SG (1) SG139747A1 (pt)
SI (1) SI1686997T1 (pt)
TN (1) TNSN06138A1 (pt)
WO (1) WO2005049032A1 (pt)
ZA (1) ZA200603905B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
KR20080004564A (ko) 2005-05-02 2008-01-09 노파르티스 아게 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드유도체
JP5129123B2 (ja) 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR101351682B1 (ko) * 2005-07-20 2014-01-14 피터 발렌트 전신 비만세포증 치료용 조성물
CN101321532B (zh) * 2005-12-06 2011-06-29 诺瓦提斯公司 用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CN101951910B (zh) * 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
EP3076966A2 (en) 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
HUT74464A (en) 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU8477998A (en) 1997-11-13 1999-06-07 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
US20040157855A1 (en) 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
CN1625602A (zh) 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
AU2004273605B2 (en) * 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit
JP5129123B2 (ja) 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
ATE428426T1 (de) 2009-05-15
IL175578A0 (en) 2008-04-13
BRPI0416680A (pt) 2007-02-13
AU2004290902B2 (en) 2008-09-25
EP1917965A1 (en) 2008-05-07
NO20062694L (no) 2006-06-12
MXPA06005598A (es) 2006-08-11
RU2405553C1 (ru) 2010-12-10
RU2009110449A (ru) 2010-09-27
JP2011121973A (ja) 2011-06-23
ZA200603905B (en) 2008-11-26
JP2007511567A (ja) 2007-05-10
SG139747A1 (en) 2008-02-29
EP1686997B1 (en) 2009-04-15
IL229124A0 (en) 2013-12-31
TNSN06138A1 (fr) 2007-11-15
IL175578A (en) 2013-10-31
JP2013241438A (ja) 2013-12-05
HRP20090390T1 (hr) 2009-08-31
US20070213317A1 (en) 2007-09-13
KR20060101761A (ko) 2006-09-26
HK1093680A1 (en) 2007-03-09
RU2362562C2 (ru) 2009-07-27
US8124611B2 (en) 2012-02-28
MA28176A1 (fr) 2006-09-01
NZ547195A (en) 2010-06-25
CN102274230A (zh) 2011-12-14
RU2006121447A (ru) 2008-01-10
CN102274230B (zh) 2015-07-01
SI1686997T1 (sl) 2009-08-31
DE602004020654D1 (de) 2009-05-28
CN1882344A (zh) 2006-12-20
PL1686997T3 (pl) 2009-09-30
US8017621B2 (en) 2011-09-13
DK1686997T3 (da) 2009-07-27
US20100179179A1 (en) 2010-07-15
US20120157441A1 (en) 2012-06-21
JP4762150B2 (ja) 2011-08-31
CA2546189A1 (en) 2005-06-02
WO2005049032A1 (en) 2005-06-02
KR101153647B1 (ko) 2012-06-18
CN101693031A (zh) 2010-04-14
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
CA2546189C (en) 2013-04-23
EP1686997A1 (en) 2006-08-09
AU2004290902A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
IL229124A0 (en) Inhibitors with a mutant form of kit
GB0223040D0 (en) Therapeutic compounds
NO20034056D0 (no) Proliferative sykdommer
PT1983000E (pt) Método para o tratamento de esclerose múltipla através da inibição da atividade de il-17
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TW200510397A (en) Conjugated complement cascade inhibitors
ATE444296T1 (de) Analoga und prodrugs von buprenorphin
NO20044459L (no) Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner
WO2005046657A3 (en) Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
MY146509A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
AU2003255413A1 (en) Use of lck inhibitor for treatment of immunologic diseases
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
AU2003214211A1 (en) Enhancement of iron chelation therapy
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
BG105953A (bg) Метод за лечение на хронична обструктивна белодробна болест
WO2003086309A3 (en) NF-κB INHIBITORS
ZA200503703B (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor